Clinical trials: Urothelial Cancer
- Condition Urothelial Cancer
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Urothelial Cancer
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.
- Trial name
- NCT06011954
- Testing
- Enfortumab Vedotin
- Where
- 22 sites in South Korea
- Volunteers
- 228 people
- Sponsor
- Astellas Pharma Korea, Inc.
Bladder Cancer, Urocystitis
A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method…
- Conditions
- Bladder Cancer, Urocystitis, Urinary Bladder Stone, Urothelial Carcinoma
- Trial name
- NCT05337189
- Testing
- Urine DNA methylation analysis, medical imaging and/or cystoscopy and/or pathological examination
- Where
- China
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Urothelial Carcinoma
A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or…
- Trial name
- NCT03330886
- Testing
- Atezolizumab
- Where
- Argentina
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the…
- Conditions
- Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma
- Trial name
- NCT03232593
- Testing
- Atezolizumab
- Where
- 56 sites in South Korea
- Volunteers
- 1,758 people
- Sponsor
- Hoffmann-La Roche
Urologic Neoplasms
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected from medical records in Stage IV urotherial (UC) patients.
- Trial name
- YODO (NCT04052113)
- Where
- Japan
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Urothelial Carcinoma
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
The purpose of this clinical trial is to learn about the current treatment patterns, safety, and effects of the study medicine (Avelumab) for the treatment of urothelial carcinoma.
- Trial name
- NCT05431777
- Testing
- Avelumab
- Where
- 16 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.